Carmell Retained Earnings from 2010 to 2024

CTCXW Stock   0.06  0  1.96%   
Carmell Therapeutics Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings will likely drop to about -61.4 M in 2024. Retained Earnings is the cumulative amount of net income that Carmell Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-58.5 M
Current Value
-61.4 M
Quarterly Volatility
9.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Carmell Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Carmell Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Carmell Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (58.5 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Carmell Retained Earnings Regression Statistics

Arithmetic Mean(37,040,516)
Coefficient Of Variation(26.04)
Mean Deviation6,825,695
Median(32,774,456)
Standard Deviation9,644,978
Sample Variance93T
Range28.7M
R-Value(0.67)
Mean Square Error55.6T
R-Squared0.45
Significance0.01
Slope(1,439,256)
Total Sum of Squares1302.4T

Carmell Retained Earnings History

2024-61.4 M
2023-58.5 M
2022-42.4 M

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-58.5 M-61.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.